Portfolio companies

Cinclus Pharma is a Swedish late-stage biopharmaceutical company committed to improving the medical outcome for patients suffering from severe stomach acid-related disorders. Cinclus Pharma’s lead candidate, Linaprazan glurate, holds the potential to decrease the unnecessary use of antibiotics, thereby reducing the development of antimicrobial resistance.

Identity (3)

This website uses cookiesfor statistics and user experience.

This website uses cookies to improve your user experience, to provide a basis for improvement and further development of the website and to be able to direct more relevant offers to you.

Feel free to read ours privacy policy. If you agree to our use, choose Accept all. If you want to change your choice afterwards, you will find that option at the bottom of the page.

Cookies